We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

dd-cfDNA Test for Assessing Kidney Transplant Rejection Performs Strongly in Real-World Study

By LabMedica International staff writers
Posted on 18 Feb 2022

A large, real-world study has confirmed the strong performance of its donor-derived cell-free DNA (dd-cfDNA) test in assessing rejection for kidney transplant patients.

Natera, Inc. (Austin, TX, USA) has announced the results of a large, multi-center clinical experience study showing excellent positive predictive value of its Prospera kidney test. The Prospera test leverages Natera's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of dd-cfDNA in the recipient's blood. It can be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy.


Image: Prospera dd-cfDNA test (Photo courtesy of Pexels)
Image: Prospera dd-cfDNA test (Photo courtesy of Pexels)

The new study has reported the real-world impact of dd-cfDNA on patient management in a multi-center, real-world clinical cohort, including 879 patients evaluated from 33 participating clinics. Eighteen of the 28 patients with biopsy-matched high-risk Prospera dd-cfDNA test results were confirmed to have active rejection, demonstrating a reported 64% positive predictive value (PPV). Further, six of the remaining 10 patients had borderline TCMR or other pathologic conditions consistent with other types of kidney injury.

"The data indicate that incorporating dd-cfDNA testing into practice may improve physician decision making regarding renal allograft recipients," the researchers summarized.

Related Links:
Natera, Inc.


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Gold Member
Hematology Analyzer
Medonic M32B
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Latest Molecular Diagnostics News

Stool-Based DNA Testing Leads to Timely Colonoscopy
18 Feb 2022  |   Molecular Diagnostics

Groundbreaking Tool Improves Genetic Testing Accuracy
18 Feb 2022  |   Molecular Diagnostics

Biomarker Blood Test Could Predict Development of Long COVID
18 Feb 2022  |   Molecular Diagnostics